Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis
ObjectiveThe current study was designed with the aim of conducting a systematic review and meta-analysis to determine the circulating levels of visfatin in patients with chronic obstructive pulmonary disease (COPD) compared to healthy individuals.MethodsUntil March 2024, we searched the Web of Scien...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1432025/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556715169906688 |
|---|---|
| author | Nahid Aboutaleb Alireza Moradi Hamzeh Mirshekari Jahangiri Mohammad Reza Aslani Mohammad Reza Aslani |
| author_facet | Nahid Aboutaleb Alireza Moradi Hamzeh Mirshekari Jahangiri Mohammad Reza Aslani Mohammad Reza Aslani |
| author_sort | Nahid Aboutaleb |
| collection | DOAJ |
| description | ObjectiveThe current study was designed with the aim of conducting a systematic review and meta-analysis to determine the circulating levels of visfatin in patients with chronic obstructive pulmonary disease (COPD) compared to healthy individuals.MethodsUntil March 2024, we searched the Web of Science, PubMed/Medline, and Scopus databases. The analysis included case–control studies assessing the association between circulating visfatin and COPD. The random effects model was utilized to analyse the results with the help of Standard Mean of Differences (SMD) and 95% confidence interval (CI). The heterogeneity of the data was assessed using Cochrane Q and I2 values.ResultsSeven studies were eligible to be included in the meta-analysis, with the COPD and healthy (control) groups having 265 and 244 subjects, respectively. The pooled results showed that although the circulating concentration of visfatin was lower in patients with COPD, no significant difference was observed (SMD: −0.48 mg/L; 95% CI: −1.67 to 0.70; p = 0.43). Subgroup analysis revealed that visfatin levels were significantly reduced in FEV1 less than 50% (p < 0.001) and in GOLD grade I-II (p < 0.05). Visfatin was shown to be significantly associated with IL-6 (p < 0.001) and TNF-α (p < 0.01) in the correlation meta-analysis. Meta-regression analysis revealed a significant correlation between the pooled SMD visfatin and pooled SMD age (p < 0.01), BMI (p < 0.001), FEV1 (p < 0.001), and IL-6 (p < 0.001).ConclusionThe findings showed an insignificant decline in visfatin level among COPD patients, but additional research is necessary due to the heterogeneity in study results.Systematic review registrationPROSPERO (CRD42023450851), https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023450851. |
| format | Article |
| id | doaj-art-4fc6c42a15aa4d0eb23e3f5e8de923f7 |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-4fc6c42a15aa4d0eb23e3f5e8de923f72025-01-07T06:40:39ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.14320251432025Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysisNahid Aboutaleb0Alireza Moradi1Hamzeh Mirshekari Jahangiri2Mohammad Reza Aslani3Mohammad Reza Aslani4Physiology Research Center, Iran University of Medical Sciences, Tehran, IranPhysiology Research Center, Iran University of Medical Sciences, Tehran, IranPhysiology Research Center, Iran University of Medical Sciences, Tehran, IranPhysiology Research Center, Iran University of Medical Sciences, Tehran, IranLung Diseases Research Center, Ardabil University of Medical Sciences, Ardabil, IranObjectiveThe current study was designed with the aim of conducting a systematic review and meta-analysis to determine the circulating levels of visfatin in patients with chronic obstructive pulmonary disease (COPD) compared to healthy individuals.MethodsUntil March 2024, we searched the Web of Science, PubMed/Medline, and Scopus databases. The analysis included case–control studies assessing the association between circulating visfatin and COPD. The random effects model was utilized to analyse the results with the help of Standard Mean of Differences (SMD) and 95% confidence interval (CI). The heterogeneity of the data was assessed using Cochrane Q and I2 values.ResultsSeven studies were eligible to be included in the meta-analysis, with the COPD and healthy (control) groups having 265 and 244 subjects, respectively. The pooled results showed that although the circulating concentration of visfatin was lower in patients with COPD, no significant difference was observed (SMD: −0.48 mg/L; 95% CI: −1.67 to 0.70; p = 0.43). Subgroup analysis revealed that visfatin levels were significantly reduced in FEV1 less than 50% (p < 0.001) and in GOLD grade I-II (p < 0.05). Visfatin was shown to be significantly associated with IL-6 (p < 0.001) and TNF-α (p < 0.01) in the correlation meta-analysis. Meta-regression analysis revealed a significant correlation between the pooled SMD visfatin and pooled SMD age (p < 0.01), BMI (p < 0.001), FEV1 (p < 0.001), and IL-6 (p < 0.001).ConclusionThe findings showed an insignificant decline in visfatin level among COPD patients, but additional research is necessary due to the heterogeneity in study results.Systematic review registrationPROSPERO (CRD42023450851), https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023450851.https://www.frontiersin.org/articles/10.3389/fmed.2024.1432025/fullvisfatinmeta-analysisCOPDIL-6BMI |
| spellingShingle | Nahid Aboutaleb Alireza Moradi Hamzeh Mirshekari Jahangiri Mohammad Reza Aslani Mohammad Reza Aslani Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis Frontiers in Medicine visfatin meta-analysis COPD IL-6 BMI |
| title | Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis |
| title_full | Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis |
| title_fullStr | Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis |
| title_full_unstemmed | Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis |
| title_short | Circulating visfatin concentrations in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis |
| title_sort | circulating visfatin concentrations in patients with chronic obstructive pulmonary disease systematic review and meta analysis |
| topic | visfatin meta-analysis COPD IL-6 BMI |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1432025/full |
| work_keys_str_mv | AT nahidaboutaleb circulatingvisfatinconcentrationsinpatientswithchronicobstructivepulmonarydiseasesystematicreviewandmetaanalysis AT alirezamoradi circulatingvisfatinconcentrationsinpatientswithchronicobstructivepulmonarydiseasesystematicreviewandmetaanalysis AT hamzehmirshekarijahangiri circulatingvisfatinconcentrationsinpatientswithchronicobstructivepulmonarydiseasesystematicreviewandmetaanalysis AT mohammadrezaaslani circulatingvisfatinconcentrationsinpatientswithchronicobstructivepulmonarydiseasesystematicreviewandmetaanalysis AT mohammadrezaaslani circulatingvisfatinconcentrationsinpatientswithchronicobstructivepulmonarydiseasesystematicreviewandmetaanalysis |